Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT

NCT02980653 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Megestrol acetate (MA) 400 mg/day

Sponsor

TTY Biopharm

Collaborators

[object Object]